Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

View ORCID ProfileRichard A. Miller, Pramod Guru, Philippe Bauer, Jorge Robles, Christian Tomaszewski, J. Scott Overcash, Michael Waters, Miriam Cameron, Julián Olalla Sierra, James Janc, Jenny A. Rudnick, Shenshen Hu, William B. Jones, Long Kwei, Suresh Mahabhashyam, Stephen B. Willingham, Gerard Criner
doi: https://doi.org/10.1101/2021.09.13.21263406
Richard A. Miller
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard A. Miller
  • For correspondence: rmiller@corvuspharma.com
Pramod Guru
2Mayo Clinic, Jacksonville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Bauer
3Mayo Clinic, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Robles
4El Centro Regional Medical Center, El Centro, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Tomaszewski
4El Centro Regional Medical Center, El Centro, CA, USA
5University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Scott Overcash
6Sharp Grossmont Hospital, La Mesa, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Waters
7Sharp Chula Vista Medical Center, Chula Vista, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Cameron
8Holy Cross Hospital, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julián Olalla Sierra
9Hospital Costa del Sol, Marbella, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Janc
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny A. Rudnick
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shenshen Hu
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William B. Jones
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Long Kwei
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suresh Mahabhashyam
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen B. Willingham
1Corvus Pharmaceuticals, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Criner
10Temple University Hospital, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Robust polyclonal humoral immune responses have the potential to generate a diverse set of antibodies to neutralize and eliminate viruses such as SARS-CoV-2 and protect against transmission, re-infection and the evolution of variants that evade immunity. CD73 is present on subsets of human B and T cells where it plays a role in lymphocyte activation and migration. CD73 also functions as an ectoenzyme that converts AMP into immunosuppressive adenosine. We have developed a humanized anti-CD73 antibody, mupadolimab (CPI-006), that blocks CD73 enzymatic activity and activates CD73POS B cells, thereby inducing differentiation into plasmablasts, immunoglobulin class switching, and antibody secretion independent of the adenosine modulatory activity. These effects suggest mupadolimab may enhance the magnitude, diversity, and duration of anti-viral responses in patients with COVID-19. This hypothesis was tested in a dose escalation phase 1 trial in 29 hospitalized patients with COVID-19. Single doses of 0.3 mg/kg – 5 mg/kg mupadolimab were well tolerated with no drug related adverse events. Doses greater than 0.3 mg/kg resulted in rapid generation of IgG and IgM to SARS-CoV-2 significantly above titers measured in convalescent controls, with elevated IgG titers sustained for more than 6 months beyond presentation of symptoms. Based on these findings, a randomized double-blind, placebo-controlled Phase 3 study in hospitalized patients was initiated. The primary endpoint was proportion of patients alive and free from respiratory failure within 28 days. This trial was discontinued early during the period of waning COVID-19 incidence after enrolling 40 patients. Although underpowered, results from this trial suggest improvement in the primary and key secondary endpoints in patients treated with single doses of 2 mg/kg and 1 mg/kg compared to placebo. The presumed mechanism of action, stimulation of B cells, may represent a novel approach to immunotherapy of COVID-19 and other viral infections.

Competing Interest Statement

A subset of authors (RAM, JJ, JAR, SH, WBJ, LK, SM, SBW) are employees, consultants or shareholders of Corvus Pharmaceuticals. RAM and SBW are inventors on patents owned by Corvus Pharmaceuticals related to this work. All other authors have nothing additional to disclose.

Clinical Trial

NCT04734873, NCT04464395

Funding Statement

All studies presented here were funded by Corvus Pharmaceuticals.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Western Institutional Review Board, Inc; Advarra Institutional Review Board; Mayo Clinic Institutional Review Board; Sharp HealthCare Institutional Review Board; Comité de Ética de Investigación con Medicamentos del Hospital Universitario Puerta de Hierro Majadahonda.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest statement A subset of authors (RAM, JJ, JAR, SH, WBJ, LK, SM, SBW) are employees, consultants or shareholders of Corvus Pharmaceuticals. RAM and SBW are inventors on patents owned by Corvus Pharmaceuticals related to this work. All other authors have nothing additional to disclose.

Data Availability

Further information and requests for resources and/or reagents should be directed to Dr. Richard A. Miller (RMiller{at}corvuspharma.com).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Richard A. Miller, Pramod Guru, Philippe Bauer, Jorge Robles, Christian Tomaszewski, J. Scott Overcash, Michael Waters, Miriam Cameron, Julián Olalla Sierra, James Janc, Jenny A. Rudnick, Shenshen Hu, William B. Jones, Long Kwei, Suresh Mahabhashyam, Stephen B. Willingham, Gerard Criner
medRxiv 2021.09.13.21263406; doi: https://doi.org/10.1101/2021.09.13.21263406
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Richard A. Miller, Pramod Guru, Philippe Bauer, Jorge Robles, Christian Tomaszewski, J. Scott Overcash, Michael Waters, Miriam Cameron, Julián Olalla Sierra, James Janc, Jenny A. Rudnick, Shenshen Hu, William B. Jones, Long Kwei, Suresh Mahabhashyam, Stephen B. Willingham, Gerard Criner
medRxiv 2021.09.13.21263406; doi: https://doi.org/10.1101/2021.09.13.21263406

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9782)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2318)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11656)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2148)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4673)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)